PUBLICATIONS

Grzymala et al. (2025). Metabolomic and Lipidomic Profiling Reveals Convergent Pathways in ADHD Therapeutics: Insights from Established and Emerging Treatments.The Journal of Pharmacology and Experimental Therapeutics.
Þorsteinsson et al. (2025). Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records. Neuropsychopharmacology.
Fontana et al. (2023). adgrl3.1-deficient zebrafish show noradrenaline-mediated externalizing behaviors, and altered expression of externalizing disorder-candidate genes, suggesting functional targets for treatment. Translational Psychiatry.
Sveinsdottir et al. (2022). Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD. Neuropsychopharmacology.
Sveinsdottir et al. (2022). Motility phenotype in a zebrafish vmat2 mutant. Plos One, 17(1).
Christensen et al. (2020) Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson’s Disease in Zebrafish. Frontiers in Behavioral Neuroscience.
Srdanovic et al.(2017) Transient knock-down of kcna2 reduces sleep in larval zebrafish. Behavioral Brain Research, 326, 13-21.
Arnason et al. (2015) Absence of rapid eye movements during sleep in adult zebrafish. Behavioral Brain Research, 291, 189-194.
Sorribes et al. (2013) The ontogeny of sleep-wake cycles in zebrafish: a comparison to humans, Frontiers in Neural Circuits, 7, 1-13.
Sigurgeirsson et al. (2013) Sleep-wake dynamics under extended light and extended dark conditions in adult zebrafish, Behavioral Brain Research, 256, 377-390.
Sigurgeirsson et al. (2011) Effects of modafinil on sleep-wake cycles in zebrafish. Zebrafish, 8(3), 133-140.
Arnardóttir et al. (2010) Dynamics of sleep-wake cyclicity at night across the human lifespan. Frontiers in Neurology.